Ikena Oncology, Inc. (IKNA)
NASDAQ
Market Cap
$79.14M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
612 of 809
Rank in Industry
336 of 445
Largest Insider Buys in Sector
IKNA Stock Price History Chart
IKNA Stock Performance
About Ikena Oncology, Inc.
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Insider Activity of Ikena Oncology, Inc.
Over the last 12 months, insiders at Ikena Oncology, Inc. have bought $0 and sold $0 worth of Ikena Oncology, Inc. stock.
On average, over the past 5 years, insiders at Ikena Oncology, Inc. have bought $8.94M and sold $797,472 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 23,419 shares for transaction amount of $86,884 was made by Bonita David P () on 2022‑06‑22.
List of Insider Buy and Sell Transactions, Ikena Oncology, Inc.
| 2022-06-22 | Bonita David P | 23,419 0.0656% | $3.71 | $86,884 | +14.75% | |||
| 2022-06-22 | OrbiMed Genesis GP LLC | 66,806 0.1792% | $3.55 | $237,161 | +14.75% | |||
| 2022-01-11 | Sale | Zhang Xiaoyan Michelle | Chief Scientific Officer | 964 0.0026% | $12.00 | $11,568 | -63.56% | |
| 2021-12-14 | Sale | FORMELA JEAN FRANCOIS | director | 5,959 0.0217% | $14.00 | $83,426 | -63.59% | |
| 2021-12-14 | Sale | Atlas Venture Fund XI, L.P. | 10 percent owner | 5,959 0.0217% | $14.00 | $83,426 | -63.59% | |
| 2021-12-13 | Sale | FORMELA JEAN FRANCOIS | director | 8,330 0.0307% | $14.64 | $121,951 | -64.74% | |
| 2021-12-13 | Sale | Atlas Venture Fund XI, L.P. | 10 percent owner | 8,330 0.0307% | $14.64 | $121,951 | -64.74% | |
| 2021-12-10 | Sale | FORMELA JEAN FRANCOIS | director | 11,989 0.0457% | $15.03 | $180,195 | -64.33% | |
| 2021-12-10 | Sale | Atlas Venture Fund XI, L.P. | 10 percent owner | 11,989 0.0457% | $15.03 | $180,195 | -64.33% | |
| 2021-12-10 | Sale | Zhang Xiaoyan Michelle | Chief Scientific Officer | 1,000 0.0037% | $14.76 | $14,760 | -64.33% | |
| 2021-03-30 | ORBIMED ADVISORS LLC | director | 423,400 6.8729% | $16.00 | $6.77M | -49.34% | ||
| 2021-03-30 | Bonita David P | director | 423,400 6.8729% | $16.00 | $6.77M | -49.34% | ||
| 2021-03-30 | FORMELA JEAN FRANCOIS | director | 125,000 2.0291% | $16.00 | $2M | -49.34% | ||
| 2021-03-30 | Atlas Venture Fund XI, L.P. | 10 percent owner | 125,000 2.0291% | $16.00 | $2M | -49.34% |
Insider Historical Profitability
<0.0001%
| Bonita David P | 1936097 4.012% | $1.64 | 2 | 0 | <0.0001% | |
| OrbiMed Genesis GP LLC | 1912678 3.9634% | $1.64 | 1 | 0 | +14.75% | |
| ORBIMED ADVISORS LLC | director | 1845872 3.825% | $1.64 | 1 | 0 | <0.0001% |
| FORMELA JEAN FRANCOIS | director | 1241935 2.5735% | $1.64 | 1 | 3 | <0.0001% |
| Atlas Venture Fund XI, L.P. | 10 percent owner | 1241935 2.5735% | $1.64 | 1 | 3 | <0.0001% |
| Zhang Xiaoyan Michelle | Chief Scientific Officer | 44475 0.0922% | $1.64 | 0 | 2 |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| Atlas Venture Life Science Advisors Llc | $7.13M | 10.4 | 5.02M | 0% | +$0 | 0.68 | |
| Bvf Inc Il | $6.77M | 9.88 | 4.77M | 0% | +$0 | 0.05 | |
| Blue Owl Capital Holdings Lp | $5.53M | 8.06 | 3.89M | +99.17% | +$2.75M | 1.04 | |
| OrbiMed | $5.03M | 7.33 | 3.54M | 0% | +$0 | 0.1 | |
| Omega Fund Management Llc | $3.19M | 4.66 | 2.25M | 0% | +$0 | 2.37 | |
| BlackRock | $2.6M | 3.79 | 1.83M | -1.58% | -$41,753.67 | <0.0001 | |
| The Vanguard Group | $2.18M | 3.18 | 1.53M | +0.48% | +$10,395.82 | <0.0001 | |
| Verition Fund Management Llc | $1.61M | 2.35 | 1.13M | -14.2% | -$266,548.28 | 0.02 | |
| Renaissance Technologies | $1.1M | 1.61 | 776,600 | New | +$1.1M | <0.01 | |
| Geode Capital Management | $848,218.00 | 1.24 | 597,277 | +12.83% | +$96,438.99 | <0.0001 | |
| Nea Management Company Llc | $809,471.00 | 1.18 | 570,050 | 0% | +$0 | 0.01 | |
| Jacobs Levy Equity Management | $729,085.00 | 1.06 | 513,440 | +813.68% | +$649,288.08 | <0.01 | |
| State Street | $685,356.00 | 1 | 482,645 | +17.5% | +$102,098.01 | <0.0001 | |
| Acuitas Investments, LLC | $564,799.00 | 0.82 | 397,746 | New | +$564,799.00 | 0.3 | |
| Adage Capital Partners Gp L L C | $408,818.00 | 0.6 | 287,900 | 0% | +$0 | <0.01 | |
| Acadian Asset Management | $400,000.00 | 0.59 | 282,782 | +1,201.82% | +$369,273.86 | <0.01 | |
| Two Sigma | $345,003.00 | 0.5 | 242,960 | +377.02% | +$272,678.18 | <0.01 | |
| Northern Trust | $332,662.00 | 0.49 | 234,269 | -1.8% | -$6,110.26 | <0.0001 | |
| Barclays | $280,000.00 | 0.41 | 196,820 | -19.55% | -$68,051.01 | <0.0001 | |
| Citadel Advisors LLC | $225,801.00 | 0.33 | 159,015 | -10.75% | -$27,210.00 | <0.0001 | |
| Sofinnova | $164,311.00 | 0.24 | 115,712 | 0% | +$0 | <0.0001 | |
| Marshall Wace | $125,941.00 | 0.18 | 88,691 | New | +$125,941.00 | <0.0001 | |
| Charles Schwab | $122,043.00 | 0.18 | 85,946 | 0% | +$0 | <0.0001 | |
| Bridgeway Capital Management | $116,866.00 | 0.17 | 82,300 | -42.67% | -$86,975.00 | <0.01 | |
| Two Sigma Advisers LP | $113,458.00 | 0.17 | 79,900 | New | +$113,458.00 | <0.0001 | |
| Tealwood Asset Management | $103,504.00 | 0.15 | 72,890 | New | +$103,504.00 | 0.02 | |
| Goldman Sachs | $103,088.00 | 0.15 | 72,597 | +207.68% | +$69,583.01 | <0.0001 | |
| BNY Mellon | $100,735.00 | 0.15 | 70,940 | +2.46% | +$2,415.43 | <0.0001 | |
| Morgan Stanley | $70,205.00 | 0.1 | 49,440 | -27.91% | -$27,174.62 | <0.0001 | |
| Dimensional Fund Advisors | $54,843.00 | 0.08 | 38,621 | -0.03% | -$17.04 | <0.0001 | |
| Cornercap Investment Counsel Inc | $51,343.00 | 0.08 | 36,157 | 0% | +$0 | 0.01 | |
| Nuveen | $51,578.00 | 0.08 | 36,322 | 0% | +$0 | <0.0001 | |
| Xtx Topco Ltd | $50,086.00 | 0.07 | 35,272 | New | +$50,086.00 | <0.01 | |
| UBS | $46,504.00 | 0.07 | 32,749 | +55.28% | +$16,555.93 | <0.0001 | |
| RhumbLine Advisers | $39,485.00 | 0.06 | 27,813 | +3.34% | +$1,277.69 | <0.0001 | |
| Bank of America | $27,300.00 | 0.04 | 19,226 | -61.53% | -$43,672.05 | <0.0001 | |
| Prudential Financial | $24,026.00 | 0.04 | 16,920 | New | +$24,026.00 | <0.0001 | |
| American International Group | $21,662.00 | 0.03 | 15,255 | -0.85% | -$186.02 | <0.0001 | |
| New York State Common Retirement Fund | $21,000.00 | 0.03 | 14,992 | 0% | +$0 | <0.0001 | |
| Ensign Peak Advisors Inc | $19,587.00 | 0.03 | 13,794 | -84.73% | -$108,650.06 | <0.0001 | |
| JPMorgan Chase | $18,945.00 | 0.03 | 13,341 | -40.25% | -$12,763.49 | <0.0001 | |
| SG Americas Securities, LLC | $18,000.00 | 0.03 | 12,490 | -38.24% | -$11,142.99 | <0.0001 | |
| Wells Fargo | $15,450.00 | 0.02 | 10,880 | +14.82% | +$1,993.73 | <0.0001 | |
| Invesco | $14,424.00 | 0.02 | 10,158 | 0% | +$0 | <0.0001 | |
| Atom Investors Lp | $14,420.00 | 0.02 | 10,155 | New | +$14,420.00 | <0.01 | |
| Tower Research Capital | $12,678.00 | 0.02 | 8,928 | +78.74% | +$5,584.97 | <0.0001 | |
| Citigroup | $8,242.00 | 0.01 | 5,804 | +25.33% | +$1,665.72 | <0.0001 | |
| Fidelity Investments | $8,237.00 | 0.01 | 5,801 | -99.86% | -$5.93M | <0.0001 | |
| CalSTRS | $4,991.00 | 0.01 | 3,515 | -31.01% | -$2,243.47 | <0.0001 | |
| Legal & General | $2,904.00 | <0.01 | 2,045 | 0% | +$0 | <0.0001 |